Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Nevus Anemicus : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Multimedia
References

Related Articles
Vitiligo




Patient Education
Click here for patient education.



Author: Theresa G Knoepp, MD, Consulting Staff, Anderson Dermatology and Skin Surgery Center, LLC

Coauthor(s): Loretta Davis, MD, Professor, Department of Internal Medicine, Division of Dermatology, Medical College of Georgia

Editors: Carrie L Kovarik, MD, Assistant Professor, Department of Dermatology and Dermatopathology, University of Pennsylvania School of Medicine; David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic; Jeffrey J Miller, MD, Associate Professor, Department of Dermatology, Penn State University, Milton S Hershey Medical Center; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System

Author and Editor Disclosure

Synonyms and related keywords: hypopigmentation, nevi anemicus, familial cutis tricolor, phakomatosis pigmentovascularis, benign nevi, congenital nevi

Background

Nevus anemicus is a congenital localized vascular anomaly that presents clinically as a hypopigmented macule or patch (see Image 1). This disorder is due to a localized hypersensitivity to catecholamines. It is an uncommon disorder and was first described by Vorner in 1906.

Pathophysiology

Intralesional injection of bradykinin, acetylcholine, serotonin, nicotine, 5-hydroxytryptamine, and histamine fails to induce the anticipated vasodilatation or erythema in the affected area. However, erythema does follow an axillary sympathetic block or intradermal injection of the alpha-adrenergic blocking agent, pilocarpine. These findings suggest that nevus anemicus is best termed a pharmacologic nevus resulting from increased vascular sensitivity to catecholamines. This conclusion is further supported by autograft exchange transplantation studies that show donor site dominance. It also has been proposed that an abnormality in endothelial adhesion molecule induction (E selectin expression) may be involved, suggesting several pharmacologic anomalies are involved and further supporting the idea that nevus anemicus may best be termed a pharmacologic nevus.

Frequency

United States

The prevalence of nevus anemicus is not known, but it is not rare.

Mortality/Morbidity

Lesions of nevus anemicus usually persist unchanged throughout life. They are asymptomatic.

Race

No racial predilection has been noted in the literature.

Sex

Nevus anemicus appears more frequently in females.

Age

Nevus anemicus may be present at birth or appear in early childhood.



History

Patients typically present with an asymptomatic pale macule or patch that has been present since birth and grows with the child. Frequently, the lesion of nevus anemicus is noted as an incidental finding on skin examination.

Physical

Clinically, nevus anemicus is a circumscribed, rounded, oval or linear pale macule or patch with irregular margins that may be surrounded by satellite macules. Lesions may be single or multiple and may be located on any part of the body, but most lesions commonly are found on the upper chest. They occur more frequently in females and are usually asymptomatic. Nevus anemicus may be present at birth or appear in early childhood, although it may be easy to overlook.

Nevus anemicus usually persists unchanged throughout life. Lesions occur with increased frequency in patients with neurofibromatosis. Areas of nevus anemicus frequently are extensive and have been observed in close association with macular telangiectatic nevi of port-wine stain type, a phenomenon attributed to somatic recombination. Nevus anemicus also has been described in patients with phakomatosis pigmentovascularis, a syndrome characterized by vascular and melanocytic nevi. Phakomatosis pigmentovascularis type IIa has been associated with primary choroidal melanoma.

Causes

Nevus anemicus results from a congenital anomaly in which hypersensitivity is localized to catecholamines. Reports describe nevus anemicus as part of a familial cutis tricolor with a suggested paradominant inheritance.



Vitiligo

Other Problems to be Considered

Hypochromic nevi
Nevus depigmentosus



Procedures

  • Nevus anemicus can be distinguished from various segmental hypomelanoses, such as vitiligo and hypochromic nevi, by diascopy. With diascopy, nevus anemicus becomes indistinguishable from the blanched surrounding skin. Loss of melanin does not occur in the lesion. Wood lamp examination does not accentuate it and may make the lesion inapparent, unlike true depigmenting disorders. The application of friction, cold, or heat will not produce changes within the lesion. Thus, scratching a line across both the lesion and normal surrounding skin will produce erythema in the normal skin but not within the lesion. Lesions of tuberculoid leprosy are anesthetic or hypesthetic; patients lose the ability to distinguish heat and cold.

Histologic Findings

The histology of nevus anemicus is normal, and melanocytes are preserved and normally distributed. Electron microscopy fails to detect abnormalities in the vascular structure.



Medical Care

Treatment generally is not required. Patients troubled by the cosmetic appearance may benefit from the application of camouflage makeup.



No therapy is available.



Prognosis

  • The prognosis of nevus anemicus is excellent.



Media file 1:  Ill-defined, asymptomatic hypopigmented patch of nevus anemicus on the lateral leg.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Photo



  • Alagheband M, Engineer L. Nevus anemicus. Skin and Aging. 1998;11:60.
  • Baba M, Seckin D, Akcali C, Happle R. Familial cutis tricolor: a possible example of paradominant inheritance. Eur J Dermatol. Jul-Aug 2003;13(4):343-5. [Medline].
  • Greaves MW, Birkett D, Johnson C. Nevus anemicus: a unique catecholamine-dependent nevus. Arch Dermatol. Aug 1970;102(2):172-6. [Medline].
  • Mountcastle EA, Diestelmeier MR, Lupton GP. Nevus anemicus. J Am Acad Dermatol. Apr 1986;14(4):628-32. [Medline].
  • Requena L, Sangueza OP. Cutaneous vascular anomalies. Part I. Hamartomas, malformations, and dilation of preexisting vessels. J Am Acad Dermatol. Oct 1997;37(4):523-49; quiz 549-52. [Medline].
  • Tran HV, Zografos L. Primary choroidal melanoma in phakomatosis pigmentovascularis IIa. Ophthalmology. Jul 2005;112(7):1232-5. [Medline].

Nevus Anemicus excerpt

Article Last Updated: Feb 21, 2007